Exoderil, 1% 20 ml

Pharmacological group:

antifungal agent

ATC code: D01AE22

Pharmacodynamics

Naftifin is an antifungal agent for external use, belonging to the class of allilamines. The mechanism of action is related to inhibition of squalene-2,3-epoxidase, which leads to reduction of formation of ergosterol, which is a part of the cell wall of the fungus. It is active against dermatophytes such as Trichophyton, Epidermophyton and Microsporum, molds (Aspergillus spp.), yeasts (Candida spp., Pityrosporum) and other fungi (such as Sporothrix schenckii).

With respect to dermatophytes and aspergillus naphthifin acts fungicidal. Against yeast fungi the drug has fungicidal or fungistatic activity depending on the strain of the microorganism. It has antibacterial activity against Gram-positive and Gram-negative microorganisms that can cause secondary bacterial infections. It has anti-inflammatory activity, which contributes to the rapid disappearance of symptoms of inflammation, especially itching.

Pharmacokinetics

Naftifin quickly penetrates the skin, creating sustained antifungal concentrations in its various layers, making once-daily use possible

Indications

– fungal infections of the skin and skin folds (tinea corporis, tinea inguinalis), incl. interdigital mycoses (tinea manum, tinea pedum);

– fungal nail infections (onychomycosis);

– skin candidiasis;

– pityriasis versicolor;

– ringworm (with or without accompanying itching).

Exoderil® is effective in the treatment of mycoses affecting areas of the skin with hyperkeratosis, as well as in areas of hair growth.

Pharmacological effect

Pharmacological group:

antifungal agent

ATX code: D01AE22

Pharmacodynamics

Naftifine is an antifungal agent for external use, belonging to the class of allylamines. The mechanism of action is associated with inhibition of squalene-2,3-epoxidase, which leads to a decrease in the formation of ergosterol, which is part of the cell wall of the fungus. Active against dermatophytes such as Trichophyton, Epidermophyton and Microsporum, molds (Aspergillus spp.), yeasts (Candida spp., Pityrosporum) and other fungi (for example, Sporothrix schenckii).

Naftifine has a fungicidal effect against dermatophytes and aspergillus. Against yeast fungi, the drug exhibits fungicidal or fungistatic activity depending on the strain of the microorganism. It has antibacterial activity against gram-positive and gram-negative microorganisms that can cause secondary bacterial infections. It has an anti-inflammatory effect, which contributes to the rapid disappearance of symptoms of inflammation, especially itching.

Pharmacokinetics

Naftifine quickly penetrates the skin, creating stable antifungal concentrations in its various layers, which makes it possible to use it once a day

Special instructions

Precautions for use:

Exoderil® is not intended for use in ophthalmology. The drug should not come into contact with the eyes.

Impact on the ability to drive vehicles and other mechanisms:

Exoderil® does not have a negative effect on the ability to drive vehicles and perform other activities that require concentration and speed of psychomotor reactions.

Active ingredient

Naftifin

Composition

1 ml of solution contains:

active substance:

naftifine hydrochloride – 10 mg;

excipients:

propylene glycol – 50 mg,

ethanol – 400 mg,

purified water – 475 mg.

Contraindications

Hypersensitivity to naftifine or propylene glycol; pregnancy and lactation (safety and effectiveness of use have not been determined).

Application of the drug to the wound surface is contraindicated.

With caution

Children’s age (experience of clinical use is limited).

Side Effects

In some cases, local reactions may be observed: dry skin, skin hyperemia and burning.

Side effects are reversible and do not require discontinuation of treatment.

Interaction

There were no drug interactions between Exoderil® and other drugs.

Overdose

No cases of overdose have been reported.

Storage conditions

Store out of the reach of children at a temperature not exceeding 30°C.

Shelf life

5 years.

Manufacturer

Globopharm Pharmaceutical Products, Australia